Centessa Pharmaceuticals (CNTA) Accounts Payables (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Accounts Payables data on file, last reported at $10.7 million in Q1 2026.

• Quarterly Accounts Payables rose 107.68% year-over-year to $10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 million (up 107.68% YoY) and the FY2025 annual result came in at $7.6 million, up 6.15% from the prior year.
• Accounts Payables improved to $10.7 million in Q1 2026 per CNTA's latest filing, from $7.6 million in the prior quarter.
• Across five years, Accounts Payables topped out at $14.4 million in Q1 2023 and bottomed at $5.1 million in Q1 2025.
• The 5-year median for Accounts Payables is $8.2 million (2022), against an average of $9.0 million.
• The widest annual swing landed in 2023, when Accounts Payables soared 114.8%; it then slumped 52.01% in 2024.
• Tracing CNTA's Accounts Payables over 5 years: stood at $13.8 million in 2022, then slipped by 14.61% to $11.8 million in 2023, then slumped by 39.54% to $7.1 million in 2024, then climbed by 6.15% to $7.6 million in 2025, then surged by 40.57% to $10.7 million in 2026.
• Per Business Quant, the three latest CNTA Accounts Payables figures stand at $10.7 million (Q1 2026), $7.6 million (Q4 2025), and $8.7 million (Q3 2025).

Peer Comparison